Article

Number of Shares and Voting Rights of Innate Pharma as of October 3, 2023

Retrieved on: 
Monday, October 9, 2023
Pharmaceutical, Professional Services, Health, Finance, Article, Treasury, AMF, AGAP, Holding company, Security (finance)

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds.

Key Points: 
  • (1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds.
  • In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.
  • The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e.
  • (2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights.

Alentis Therapeutics Appoints Lung Experts Professors Tony Mok and Steven Nathan to its Scientific Advisory Board

Retrieved on: 
Thursday, October 5, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Aurora, Histology, Chinese University of Hong Kong, Multimedia, Science, Lung cancer, Biomarker, Chinese, University, Cedars-Sinai Medical Center, CLDN1, Abstract, Lung transplantation, The New England Journal of Medicine, AACR, Anesthesiology, Clinical Oncology, Clarivate, Long Island Jewish Medical Center, Book, Coronavirus Scientific Advisory Board, IPF, Respiratory therapist, University of the Witwatersrand School of Chemical and Metallurgical Engineering, Food and Drug Administration, Lung, US Food Sovereignty Alliance, Medical director, Patient, Idiopathic pulmonary fibrosis, AstraZeneca, ESMO, Therapy, Article, Publication, Long Island, ASCO, Pulmonary hypertension, CSCO, Research, Inova Fairfax Hospital, Pharmaceutical industry, Medical device, Vaccine

Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Tony Mok, Professor of Clinical Oncology at the Chinese University of Hong Kong and Steven Nathan, Professor at the University of Virginia as members of its Scientific Advisory Board.

Key Points: 
  • Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Tony Mok, Professor of Clinical Oncology at the Chinese University of Hong Kong and Steven Nathan, Professor at the University of Virginia as members of its Scientific Advisory Board.
  • View the full release here: https://www.businesswire.com/news/home/20231005193827/en/
    Lung experts Prof. Steven Nathan and Prof. Tony Mok join Alentis Therapeutics' Scientific Advisory Board.
  • (Photo: Alentis Therapeutics)
    “Tony and Steven have exceptional expertise in lung cancer and lung fibrosis, respectively, which will be of great value to our Scientific Advisory Board,” said Dr. Luigi Manenti, Chief Medical Officer of Alentis.
  • Prof. Steven Nathan is the Medical Director of the Advanced Lung Disease and Lung Transplant Program at Inova Fairfax Hospital and is a Professor at the University of Virginia.

Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination

Retrieved on: 
Wednesday, October 11, 2023
DECA, Electric Bond and Share Company v. Securities and Exchange Commission, Article, Security (finance)

NEW YORK, Oct. 11, 2023 /PRNewswire/ -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the "Company") announced today that the Company's shareholders voted in favor of approving amendments to the Company's amended and restated memorandum and articles of association (the "Articles") to, amongst other things, extend the date by which the Company must consummate an initial business combination from October 11, 2023 to July 11, 2024 by electing to extend the date to consummate an initial business combination on a monthly basis for up to nine times by an additional one month each time (the "Extension").

Key Points: 
  • NEW YORK, Oct. 11, 2023 /PRNewswire/ -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the "Company") announced today that the Company's shareholders voted in favor of approving amendments to the Company's amended and restated memorandum and articles of association (the "Articles") to, amongst other things, extend the date by which the Company must consummate an initial business combination from October 11, 2023 to July 11, 2024 by electing to extend the date to consummate an initial business combination on a monthly basis for up to nine times by an additional one month each time (the "Extension").
  • The Company also announced today that an aggregate of $50,000 has been deposited into the Company's trust account to extend the period of time the Company has to consummate its initial business combination by an additional month in accordance with the amended terms of the Articles.
  • A Current Report on Form 8-K disclosing the full voting results will be filed with the U.S. Securities and Exchange Commission (the "SEC").

Fuller, Smith & Turner PLC: Transaction in Own Shares

Retrieved on: 
Wednesday, October 4, 2023
FSA, Article, Transparency, Disclosure, European Union (Withdrawal) Act 2018, Security (finance), Treasury, EU

The Company intends to hold the repurchased shares in Treasury.

Key Points: 
  • The Company intends to hold the repurchased shares in Treasury.
  • Following the purchase of the said shares, Fuller’s listed issued share capital consists of 41,082,339 ‘A’ ordinary shares of 40p each.
  • Of this total, 2,906,237 ‘A’ ordinary shares are held in treasury.
  • Therefore, the total number of listed voting rights in the Company for the purpose of Disclosure and Transparency Rule 5.6.1 (calculated in accordance with Disclosure and Transparency Rule 5.6.2) is 38,176,102.

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES

Retrieved on: 
Wednesday, October 4, 2023
Overload, Exercise, Heart failure, Finance Secretary (India), Liver disease, Disclosure, Cancer, Article, Consultant, EUR, Brussels Stock Exchange, RSU, Security (finance)

Ghent, Belgium, 4 October 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces that, in the framework of the "restricted share unit" or "RSU" plan for non-executive independent directors as approved by the Company's extraordinary shareholders' meeting of 10 February 2023, the Company's share capital has increased on 4 October 2023 from EUR 2,921,010.22 to EUR 2,926,295.90 and the number of issued and outstanding shares has further increased from 28,191,733 to 28,242,753 ordinary shares, through the issuance of a total of 51,020 new shares that were subscribed for in the capital increase.

Key Points: 
  • Ghent, Belgium, 4 October 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces that, in the framework of the "restricted share unit" or "RSU" plan for non-executive independent directors as approved by the Company's extraordinary shareholders' meeting of 10 February 2023, the Company's share capital has increased on 4 October 2023 from EUR 2,921,010.22 to EUR 2,926,295.90 and the number of issued and outstanding shares has further increased from 28,191,733 to 28,242,753 ordinary shares, through the issuance of a total of 51,020 new shares that were subscribed for in the capital increase.
  • The total current number of outstanding subscription rights amounts to 4,058,822, which entitles their holders (if exercised) to subscribe to 3,819,135 new shares with voting rights in total, namely:
    up to 261,895 new shares can be issued upon the exercise of 90,780 share options that are still outstanding under the 'Executive Share Options' plan for staff members and consultants of the Company, entitling the holder thereof to acquire ca.
  • 2.88 new shares when exercising one of his or her share options (the "Executive Share Options");
    up to 984,138 new shares can be issued upon the exercise of 984,138 share options (each share option having the form of a subscription right) that are still outstanding under the '2018 Share Options' plan for directors, employees and other staff members of the Company and its subsidiaries, entitling the holder thereof to acquire one new share when exercising one of his or her share options (the "2018 Share Options");
    up to 997,600 new shares can be issued upon the exercise of 997,600 share options (each share option having the form of a subscription right) that are still outstanding under the '2021 Share Options' plan for directors, employees and other staff members of the Company and its subsidiaries, entitling the holder thereof to acquire one new share when exercising one of his or her share options (the "2021 Share Options");
    up to 302,804 new shares can be issued to Bootstrap Europe S.C.SP.
  • upon the exercise of 10 warrants (each warrant having the form of a subscription right) that are still outstanding that have been issued by the extraordinary shareholders meeting of 27 May 2022 (the "Bootstrap Warrants");
    up to 161,404 new shares can be issued to Kreos Capital VII Aggregator SCSp.

Elanco Announces Corporate Governance Enhancements

Retrieved on: 
Wednesday, October 4, 2023
Health, Consumer, Agriculture, Pets, Natural Resources, Veterinary, IPO, Elanco, Article, Securities and Exchange Commission (Philippines), ELAN, Annual general meeting, Security (finance), NYSE, Audit

Elanco Animal Health Incorporated (NYSE: ELAN) announced today that the Board of Directors has commenced a process to amend the Company’s corporate governing documents as part of a comprehensive governance review following the Company’s 2023 Annual Meeting of Shareholders.

Key Points: 
  • Elanco Animal Health Incorporated (NYSE: ELAN) announced today that the Board of Directors has commenced a process to amend the Company’s corporate governing documents as part of a comprehensive governance review following the Company’s 2023 Annual Meeting of Shareholders.
  • “We have engaged with our shareholders, particularly during the past three years, on corporate governance matters,” said R. David Hoover, Chairman of the Board and the Corporate Governance Committee.
  • “Given the solid foundation Elanco has built during the five years since our IPO, we believe now is the time to make these additional governance changes.
  • At Elanco, we are committed to strong corporate governance and will continue to foster open communication with our shareholders.”
    More information regarding the proposals requiring shareholder approval will be included in the Company’s proxy statement to be filed with the Securities and Exchange Commission prior to the 2024 Annual Meeting of Shareholders.

Fuller, Smith & Turner PLC: Transaction in Own Shares

Retrieved on: 
Tuesday, October 3, 2023
FSA, Article, Transparency, Disclosure, European Union (Withdrawal) Act 2018, Security (finance), Treasury, EU

The Company intends to hold the repurchased shares in Treasury.

Key Points: 
  • The Company intends to hold the repurchased shares in Treasury.
  • Following the purchase of the said shares, Fuller’s listed issued share capital consists of 41,082,339 ‘A’ ordinary shares of 40p each.
  • Of this total, 2,886,237 ‘A’ ordinary shares are held in treasury.
  • Therefore, the total number of listed voting rights in the Company for the purpose of Disclosure and Transparency Rule 5.6.1 (calculated in accordance with Disclosure and Transparency Rule 5.6.2) is 38,196,102.

Ferguson Share Repurchase Program - Weekly Report

Retrieved on: 
Tuesday, October 3, 2023
HVAC, Manufacturing, Treasury, Article, Ferguson, Disclosure, European Union (Withdrawal) Act 2018, Security (finance), EU

The Company intends to hold these shares in treasury.

Key Points: 
  • The Company intends to hold these shares in treasury.
  • Following the purchase of these shares (including those purchased but not yet settled), the number of shares held by the Company in treasury will be 28,307,378.
  • Following the purchase of these shares, the remaining number of ordinary shares in issue will be 203,863,804.
  • In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018, and the Commission Delegated Regulation (EU) 2016/1052, detailed information about the individual purchases can be found at Ferguson - Investors - Shareholder Center - Share Buy-Back Details - 2023 Share Buy-Back .

ARMA Instruments Launch Zero Trust G1 Mark II Secure Messaging Communication Device

Retrieved on: 
Tuesday, October 3, 2023
Other Defense, Contracts, Security, Data Management, Other Communications, Government Technology, Technology, Communications, Apps, Applications, Defense, Drones, Military, Other Technology, Telecommunications, Software, Networks, Midnight, GPS, SIM, Smartphone, Article, G1, Intelligence, Identity, Multimedia, ARMA, Privacy, Terrorism, TETRA, NFC, Silicon, Trust, Non-governmental organization, Human rights, Sandworm, Bluetooth, Ad Donker, Tor, Environment, Arms industry, Mobile phone, Risk management

View the full release here: https://www.businesswire.com/news/home/20231002887540/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231002887540/en/
    Switzerland-based ARMA Instruments AG announces the launch of their ARMA G1 Mark II Secure Messaging Device.
  • Developed with zero trust principles, the device is a closed mobile system for person-to-person messaging at the highest security levels to counter advanced adversary attacks.
  • (Photo: Business Wire)
    In this environment of advanced global threats, Switzerland-based ARMA Instruments AG announces the launch of their ARMA G1 Mark II Secure Messaging Device in Kyiv this month.
  • For more information on the Kyiv and 24 October Silicon Valley event visit: https://armainstruments.com/launching-the-arma-g1-mark-2-events/
    ARMA Instruments is a secure communication systems technology provider and creator of the world’s first secure communications messaging device, the ARMA G1.

Fuller, Smith & Turner PLC: Transaction in own securities

Retrieved on: 
Monday, October 2, 2023
FSA, Article, Transparency, Disclosure, European Union (Withdrawal) Act 2018, Security (finance), Treasury, EU

The Company intends to hold the repurchased shares in Treasury.

Key Points: 
  • The Company intends to hold the repurchased shares in Treasury.
  • Following the purchase of the said shares, Fuller’s listed issued share capital consists of 41,082,339 ‘A’ ordinary shares of 40p each.
  • Of this total, 2,866,237 ‘A’ ordinary shares are held in treasury.
  • Therefore, the total number of listed voting rights in the Company for the purpose of Disclosure and Transparency Rule 5.6.1 (calculated in accordance with Disclosure and Transparency Rule 5.6.2) is 38,216,102.